Latest news with #REFLECT
Saba Yemen
3 days ago
- Science
- Saba Yemen
Scientists launch project to cool earth using marine clouds
London - Saba: A team of scientists at the University of Manchester has launched a project exploring the potential of marine cloud brightening as a temporary measure to mitigate global warming. The project, funded by the UK's Advanced Research and Invention Agency (ARIA), aims to study how spraying sea salt particles can enhance clouds' ability to reflect sunlight, redirecting solar radiation back into space and contributing to lower temperatures on Earth. The team also seeks to assess the impact of this technology on the global climate while considering potential environmental risks. The project is based on marine cloud brightening technology, which involves spraying fine sea salt particles into low-lying clouds over oceans. This process is expected to increase cloud reflectivity by 5-10%, potentially leading to a temporary temperature drop in specific regions—a crucial effect in combating worsening global warming. Preliminary studies suggest that this technique could reduce temperatures within a limited range of 0.5 to 1°C. However, its broader impact on the global climate remains under investigation. Professor Hugh Coe, the project's lead researcher, explained that marine cloud brightening is a temporary solution that does not address the root causes of global warming, such as greenhouse gas emissions. However, it could provide humanity with vital time to accelerate emission reductions and transition to clean energy sources. The technology relies on natural and safe sea salt, which has a short atmospheric lifespan, settling within a few days. This reversibility makes the environmental intervention more controllable compared to more radical approaches, such as stratospheric aerosol injection, whose effects are harder to manage. This project is part of broader efforts to develop innovative solutions to climate change, especially amid rising global temperatures. Dubbed "REFLECT," the project focuses on studying how microscopic sea salt particles can enhance clouds' ability to reflect sunlight back into space, potentially reducing Earth's surface temperature. Whatsapp Telegram Email Print more of (International)
Yahoo
18-05-2025
- Business
- Yahoo
Abbott Laboratories (ABT)'s Libre Linked to Fewer Heart Hospitalizations in Diabetes
Abbott Laboratories (NYSE:ABT) recently shared findings from its REFLECT real-world studies, revealing that the use of its FreeStyle Libre® continuous glucose monitoring (CGM) system is linked to a notable decrease in hospitalizations for heart-related complications among people with diabetes. For the first time, the data demonstrate that CGM technology can reduce the severity of cardiovascular issues in individuals with Type 1 diabetes, regardless of their history with low blood sugar or previous heart-related hospital stays. The studies also showed a similar drop in heart-related hospital admissions for people with Type 2 diabetes who use the Libre biowearable device while on insulin. In its announcement, Abbott Laboratories (NYSE:ABT) highlighted that diabetes affects 589 million people globally. Managing blood sugar and preventing complications like heart disease are critical challenges for those living with the condition. Ramzi Ajjan, M.D., professor of Metabolic Medicine at Leeds University and Leeds Teaching Hospitals Trust, made the following comment on this development: "I regularly treat people with diabetes who have problems with their blood vessels, resulting in heart attacks, strokes and amputations. These blood vessel problems, known collectively as cardiovascular disease, remain the main causes of ill health in people with diabetes. I am very excited to see data that show a significant reduction in cardiovascular disease-related hospital admissions. It's great to see the clear, positive impact of FreeStyle Libre technology on cardiovascular outcomes, making diabetes management more effective and improving the health of our patients." Abbott Laboratories (NYSE:ABT)'s breakthrough in diabetes is well-received by analysts, its dividend policy has also garnered investors' attention over the years. The company is a Dividend King with 53 consecutive years of dividend growth under its belt. Currently, it pays a quarterly dividend of $0.59 per share and has a dividend yield of 1.75%, as of May 18. The stock surged by over 30.6% in the past 12 months. While we acknowledge the potential of ABT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABT and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: and Disclosure. None. Sign in to access your portfolio
Yahoo
18-05-2025
- Business
- Yahoo
Abbott Laboratories (ABT)'s Libre Linked to Fewer Heart Hospitalizations in Diabetes
Abbott Laboratories (NYSE:ABT) recently shared findings from its REFLECT real-world studies, revealing that the use of its FreeStyle Libre® continuous glucose monitoring (CGM) system is linked to a notable decrease in hospitalizations for heart-related complications among people with diabetes. For the first time, the data demonstrate that CGM technology can reduce the severity of cardiovascular issues in individuals with Type 1 diabetes, regardless of their history with low blood sugar or previous heart-related hospital stays. The studies also showed a similar drop in heart-related hospital admissions for people with Type 2 diabetes who use the Libre biowearable device while on insulin. In its announcement, Abbott Laboratories (NYSE:ABT) highlighted that diabetes affects 589 million people globally. Managing blood sugar and preventing complications like heart disease are critical challenges for those living with the condition. Ramzi Ajjan, M.D., professor of Metabolic Medicine at Leeds University and Leeds Teaching Hospitals Trust, made the following comment on this development: "I regularly treat people with diabetes who have problems with their blood vessels, resulting in heart attacks, strokes and amputations. These blood vessel problems, known collectively as cardiovascular disease, remain the main causes of ill health in people with diabetes. I am very excited to see data that show a significant reduction in cardiovascular disease-related hospital admissions. It's great to see the clear, positive impact of FreeStyle Libre technology on cardiovascular outcomes, making diabetes management more effective and improving the health of our patients." Abbott Laboratories (NYSE:ABT)'s breakthrough in diabetes is well-received by analysts, its dividend policy has also garnered investors' attention over the years. The company is a Dividend King with 53 consecutive years of dividend growth under its belt. Currently, it pays a quarterly dividend of $0.59 per share and has a dividend yield of 1.75%, as of May 18. The stock surged by over 30.6% in the past 12 months. While we acknowledge the potential of ABT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABT and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-05-2025
- Health
- Yahoo
Abbott's Libre® Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes
New data reveal a 78% reduction in cardiovascular disease-related hospitalizations for people living with Type 1 diabetes with prior severe low blood sugar episodes.1 This significant decrease is linked to the use of Libre biowearable technology compared to traditional blood glucose monitors.1 Results also show a reduction in hospitalization for cardiovascular complications in adults with Type 2 diabetes on insulin using Libre technology.2 ABBOTT PARK, Ill., May 15, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from its REFLECT real-world studies that show the use of FreeStyle Libre® continuous glucose monitoring (CGM) technology is associated with a significant reduction in the risk of hospitalization for heart complications in people with diabetes. For the first time, data show that CGM technology can help lessen the severity of cardiovascular complications – regardless of a prior history of low blood sugar events or heart disease-related hospitalizations – in individuals with Type 1 diabetes.1 Findings from the studies also show a similar reduction in heart-related hospitalizations for those with Type 2 diabetes on insulin using Libre biowearable technology.2 Diabetes remains a serious chronic disease worldwide, affecting approximately 589 million people3 and often accompanied by cardiovascular complications.4 People with Type 1 and Type 2 diabetes are 2-4 times more likely than someone without diabetes to develop heart disease, a major cause of death for both groups.5 While heart risks for Type 2 diabetes are well known, there's low awareness about heart complications in people with Type 1 diabetes. Adults with Type 1 diabetes who have had serious low blood sugar episodes are twice as likely to be hospitalized for heart-related issues.6 For people with diabetes, the REFLECT findings suggest that the use of Libre technology could also potentially lead to lower healthcare costs due to the reduction in hospital admissions related to heart complications. "These results are remarkable, as we see dual benefits from CGM technology in managing diabetes and its associated cardiovascular complications," said one of the lead authors of the studies, David Nathanson, MD, PhD, Karolinska University Hospital in Sweden. "CGMs empower people to proactively manage their diabetes and make informed health choices through real-time, constant feedback on their glucose levels. This data shows that using CGMs is linked with significantly reduced hospitalizations related to heart issues, which can have a significant impact on patients, their families and the healthcare system by easing medical, emotional and financial burdens." The findings also reveal that the risk of hospitalizations for cardiovascular disease was reduced by 80% among people with Type 1 diabetes with no prior history of cardiovascular disease when using the Libre biowearable technology compared to those who used a traditional blood glucose monitor. For individuals with a prior history of cardiovascular disease, the risk of hospitalizations was reduced by 49%.1 "These data are transformative and show just how valuable FreeStyle Libre technology is for managing both diabetes and heart health, helping millions of people live healthy lives," said Mahmood Kazemi, M.D., chief medical officer for Abbott's diabetes care business. "With its heart benefits, Libre makes it easier for people to take control of their health." The REFLECT research considered a range of cardiovascular-disease related conditions including non-fatal heart attack, non-fatal stroke, coronary artery disease, heart failure, atrial fibrillation and cardiovascular death – conditions commonly seen in people with diabetes.7 "I regularly treat people with diabetes who have problems with their blood vessels, resulting in heart attacks, strokes and amputations," said Ramzi Ajjan, M.D., professor of Metabolic Medicine at University of Leeds and Leeds Teaching Hospitals NHS Trust. "These blood vessel problems, known collectively as cardiovascular disease, remain the main causes of ill health and death in people with diabetes. I am very excited to see data that show significant reduction in cardiovascular disease-related hospital admissions. It's great to see the clear, positive impact of FreeStyle Libre technology on cardiovascular outcomes, making diabetes management more effective and improving the health of our patients." About REFLECT Studies:The REFLECT studies, funded by Abbott, were real-world retrospective studies conducted using data from the Swedish National Diabetes Register (NDR), one of the largest and most comprehensive diabetes registers in the world representing approximately 90% of all patients with diabetes in Sweden.8 The studies, published between October 2024 and April 2025, assessed: 1) the impact of intermittently scanned CGM versus blood glucose monitoring on HbA1c levels and hospitalizations in adults with insulin-treated Type 2 diabetes; 2) the impact of intermittently scanned CGM versus blood glucose monitoring on hospitalization rates for metabolic and vascular complications and HbA1c levels for adults with Type 1 diabetes;9 3) the risk of cardiovascular complications after severe hypoglycemia in adults with Type 1 diabetes, and the risk of post-severe hypoglycemia cardiovascular complications for intermittently scanned CGM users versus blood glucose monitoring users. About FreeStyle Libre:Abbott continues to pioneer ground-breaking technology to support people living with diabetes. The company revolutionized diabetes care 10 years ago with its world-leading FreeStyle Libre continuous glucose monitoring portfolio, which today is used by more than 7 million people across over 60 countries.10 People use Libre technology to see their glucose numbers in real-time, providing insights into how food, activity, or insulin impacts their glucose to help them make progress on their health goals. There is full or partial reimbursement for Libre systems in more than 40 countries.11 About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at and on LinkedIn, Facebook, Instagram, X and YouTube. Product for prescription only; for Important Safety Information, please visit 1 Eeg-Olofsson, K., Diabetologia (2025): 2 Nathanson, D., Diabetologia (2024): 3 International Diabetes Federation – Facts & figures, accessed April 2025 from: 4 CDC – Diabetes and your heart, accessed April 2025 from: 5 Dal Canto, E., European J. of Preventive Cardiology (2019): 6 Amiel, SA, The Lancet Diabetes & Endocrinology (2019): 7 AHA – Cardiovascular disease and diabetes, accessed May 2025 from: Cardiovascular Disease and Diabetes |American Heart Association 8 NDR - Nationella Diabetesregistret, accessed April 2025 from: 9 Eeg-Olofsson K. Diabetes Care (2024): https: 24-0690 10 Data on file, Abbott Diabetes Care. Data based on the number of patients assigned to each manufacturer. 11 Data on file, Abbott Diabetes Care. View original content to download multimedia: SOURCE Abbott
Gulf Today
18-03-2025
- Health
- Gulf Today
Cool roofs to combat extreme heat
A global scientific trial is on that includes the city of Ahmedabad in India to study how indoor heat impacts people's health and economic outcomes in developing countries – and how 'cool roofs' might help, according to a Reuters report. Hundreds of roofs in the informal settlements of India's western Gujarat state have been painted in a reflective, white coating over the last two months to try to keep their occupants cooler as the hottest time of year approaches. The effort involves 400 households in Ahmedabad. Researchers at the University of Heidelberg in Germany are also looking at other projects in Burkina Faso, Mexico and South Pacific. Early results have also shown that reflective, white roofs have led to lower heart rates. According to the study website, the REFLECT study aims to identify whether cool roof technology can be an effective, low-cost, mass-adoptable, passive cooling intervention for high indoor air temperatures in communities affected by extreme heat. The study investigates the impact of cool roof materials on health, environmental and economic outcomes in Hermosillo, Mexico; Ouagadougou, Burkina Faso; Ahmedabad, India; and Niue, Oceania. According to an India Today report, to tackle the challenge of increased heat, in an innovative approach, the roofs of 400 houses in Ahmedabad, Gujarat, have been painted white, to analyse the impact of indoor heat on the health of individuals and to show how 'cool roofs' can help to tackle this. The white paint contains titanium dioxide, which helps in reflecting the sunlight. This trail will go on for a year, and scientists will collect health and indoor environmental data from residents living under the cool roofs – and from those who do not have it. The study is showing promising results as residents experience lower heat The India Today report quotes a lead researcher of the study who says that early results from the Burkina Faso trial show that cool roofs reduced indoor temperature by between 1.2 degrees C in tin- and mud-roofed homes and 1.7 degrees C in tin-roofed homes over two years, which subsequently lowered residents' heart rates. Understanding the impact of cool roof technology in globally diverse communities will support decision makers in investing in effective climate change adaptation measures. According to the US Environmental Protection Agency (EPA)website, a cool roof absorbs and transfers less heat from the sun to the building compared with a more conventional roof. A high solar reflectance, or albedo, is the most important characteristic to understand in terms of how well a cool roof reflects heat from the sun away from a building. A high thermal emittance - how well a cool roof sheds the heat it does absorb - also plays a role, particularly in climates that are warm and sunny. Together, these properties reduce temperatures on the roof, inside the building, and in the surrounding ambient air. Buildings with cool roofs use less air conditioning, save energy, and have more comfortable indoor temperatures. For example, in non-air-conditioned residential buildings, cool roofs can lower maximum indoor temperatures by 1.2–3.3°C (2.2 to 5.9°F). Cool roofs also impact surrounding areas by lowering temperatures outside of buildings and thus mitigating the heat island effect. The EPA website states that cool roofs provide several benefits beyond urban heat island mitigation. One, reduced energy use. A cool roof lowers the amount of heat transferred to the building, which allows it to stay cooler and use less energy for air conditioning. In air-conditioned residential buildings, solar reflectance from a cool roof can reduce peak cooling demand by 11–27%. Two, reduced air pollution and greenhouse gas emissions. By lowering energy use, cool roofs decrease the associated air pollution and greenhouse gas emissions. When applied at a scale large enough to affect ambient temperatures, cool roofs could reduce the formation of ground-level ozone (which is heat-dependent) and reduce cooling energy use across a city. Three, improved human health and comfort. Cool roofs can help reduce the adverse health impacts of heat islands, such as heat exhaustion, respiratory difficulties, dizziness and cramps, and heat-induced death. One UK study showed that cool roofs, when implemented across a city, could offset 18% of heat-related mortality associated with the heat island effect.
